When combined with baseline metabolic biomarkers (fasting glucose, insulin, lipid profile, inflammatory markers), genetic insights from the Precision Peptide test can help your provider evaluate whether GLP-1 therapy aligns with your individual risk profile and comorbidity burden
Effects of GLP-1 RAs on Promoting Pancreatic Islet -Cell Proliferation and Inhibiting Its Apoptosis GLP-1 RAs confer comprehensive benefits through the enhancement of glucose-stimulated insulin secretion, restoration of -cell glucose sensitivity, and stimulation of insulin gene expression and biosynthesis
Urine, as part of the urogenital system and an easy-to-get sample, could be a feasible matrix to look for patient biomarkers
The finding that GLP-1 receptor agonists may be associated with a modest reduction in incident depression compared to DPP-4 inhibitors suggests that these agents could offer dual benefits providing effective glycemic control while also contributing to mood stabilization
This can lead to symptoms like tiredness, weakness, low mood, pins and needles and breathlessness